A low-dose stimulation protocol using highly purified follicle-stimulating hormone can lead to high pregnancy rates in in vitro fertilization patients with polycystic ovaries who are at risk of a high ovarian response to gonadotropins.
Details
Serval ID
serval:BIB_8A8923071074
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
A low-dose stimulation protocol using highly purified follicle-stimulating hormone can lead to high pregnancy rates in in vitro fertilization patients with polycystic ovaries who are at risk of a high ovarian response to gonadotropins.
Journal
Fertility and Sterility
ISSN
0015-0282 (Print)
ISSN-L
0015-0282
Publication state
Published
Issued date
2001
Volume
75
Number
6
Pages
1131-1135
Language
english
Abstract
OBJECTIVE: To study the benefits of a low-dose stimulation (LDS) protocol with purified urinary follicle-stimulating hormone in patients with polycystic ovaries who have presented previously with a very high ovarian response to a standard hMG stimulation.
DESIGN: Cohort study.
SETTING: Fertility center in a university hospital.
PATIENT(S): Sixty-one patients involved in an IVF/ICSI program from January 1995 to December 1996.
INTERVENTION(S): The patients were first stimulated with a standard protocol using hMG and presented with a very high ovarian response. These patients were then stimulated a second time using a low-dose protocol. Cryopreserved embryos were transferred in later artificial or natural cycles until to December 1999.
MAIN OUTCOME MEASURE(S): Number of gonadotropin ampules; estradiol level on the day of ovulation induction; follicles, oocytes, and cryopreserved zygotes; fertilization, implantation, and pregnancy rates; and number of ovarian hyperstimulation syndromes (OHSS).
RESULT(S): The number of ampules used, the estradiol level reached, and the number of oocytes obtained were significantly lower under the LDS than the standard protocol. High implantation (21.8%) and clinical pregnancy (38.4%) rates were obtained after LDS. The cumulated deliveries per cycle started and per patient were, respectively, 41.6% and 52.5%. Five patients suffered OHSS with the standard protocol, and none with the LDS.
CONCLUSION(S): The LDS protocol offers a safe and efficient treatment for patients who present with echographic polycystic ovaries and are at risk of an excessive ovarian response to standard IVF stimulation protocols.
DESIGN: Cohort study.
SETTING: Fertility center in a university hospital.
PATIENT(S): Sixty-one patients involved in an IVF/ICSI program from January 1995 to December 1996.
INTERVENTION(S): The patients were first stimulated with a standard protocol using hMG and presented with a very high ovarian response. These patients were then stimulated a second time using a low-dose protocol. Cryopreserved embryos were transferred in later artificial or natural cycles until to December 1999.
MAIN OUTCOME MEASURE(S): Number of gonadotropin ampules; estradiol level on the day of ovulation induction; follicles, oocytes, and cryopreserved zygotes; fertilization, implantation, and pregnancy rates; and number of ovarian hyperstimulation syndromes (OHSS).
RESULT(S): The number of ampules used, the estradiol level reached, and the number of oocytes obtained were significantly lower under the LDS than the standard protocol. High implantation (21.8%) and clinical pregnancy (38.4%) rates were obtained after LDS. The cumulated deliveries per cycle started and per patient were, respectively, 41.6% and 52.5%. Five patients suffered OHSS with the standard protocol, and none with the LDS.
CONCLUSION(S): The LDS protocol offers a safe and efficient treatment for patients who present with echographic polycystic ovaries and are at risk of an excessive ovarian response to standard IVF stimulation protocols.
Keywords
Adult, Cohort Studies, Delivery, Obstetric, Dose-Response Relationship, Drug, Embryo Implantation, Estradiol/blood, Female, Fertilization in Vitro, Follicle Stimulating Hormone/administration & dosage, Follicle Stimulating Hormone/therapeutic use, Humans, Menotropins/adverse effects, Menotropins/therapeutic use, Oocytes, Ovarian Hyperstimulation Syndrome/chemically induced, Ovary/drug effects, Polycystic Ovary Syndrome/physiopathology, Pregnancy, Pregnancy Rate, Risk Factors, Specimen Handling, Sperm Injections, Intracytoplasmic
Pubmed
Web of science
Create date
25/01/2008 15:39
Last modification date
20/08/2019 14:49